What can we expect from MDR breast cancer imaging with sestamibi?

Journal of Nuclear Medicine

Volumn 43, Issue 4, 2002, Pages 526-530

  Palmedo, Holger ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN DERIVATIVE; DAUNORUBICIN; DOXORUBICIN; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NEUROLEPTIC AGENT; PACLITAXEL; TOREMIFENE; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

BLOOD TOXICITY; BREAST CANCER; CANCER RESISTANCE; CANCER SCINTISCANNING; CLINICAL PROTOCOL; DIARRHEA; HUMAN; MULTIDRUG RESISTANCE; NAUSEA; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; SCINTIMAMMOGRAPHY; VERTIGO;

BREAST NEOPLASMS; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; P-GLYCOPROTEINS; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI;

EID: 0036217970     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (42)

1. Multidrug resistance (mdr1) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity
2. Pharmacology of drugs that alter multidrug resistance in cancer
3. Multiple-drug resistance in human cancer
4. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene
5. Expression of a multidrug resistance gene in human cancers
6. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrugresistant human cells
7. Overexpression of a M(r) 110.000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance
8. Pharmacokinetic modeling of multidrug resistance P-glycoprotein transport of gamma-emitting substrates
9. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: Correlation with mdr gene expression
10. Characterization of multidrug resistance Pglycoprotein transport function with an organotechnetium cation
11. 201T1-thallous chloride in tumour cells: Role of P-glycoprotein
12. Effects of induction of multidrug resistance on accumulation of Tc-99m sestamibi in vitro
13. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients
14. Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression
15. Fractional retention of technetium-99m-sestamibi as an index of glycoprotein P-expression in untreated breast cancer patients
16. Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors
17. 99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer
18. Practical treatment for dose individualisation in cancer chemotherapy
19. Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer
20. Influence of the heterogeneity of P-glycoprotein expression on technetium-99m-MIBI uptake in breast cancer
21. 99mTc-MIBI scintimammography
22. Diagnostic accuracy of Tc-99m sestamibi breast imaging: Multicenter trial results
23. Scintimammography with technetium-99m methoxyisobutylisonitrile: Results of a prospective European multicentre trial
24. Expression of a complementary DNA library transfer establishes mrp as a multidrug resistance gene
25. Comparison of the accumulation and efflux kinetics of technetium-99m sestamibi and technetium-99m tetrofosmin in an MRP-expressing tumour cell line
26. Involvement of glutathione in loss of technetium-99m-MIBI accumulation related to membrane MDR protein expression in tumor cells
27. 99mTc-Sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein
28. P-glycoprotein and multidrug resistance-related protein expressions in relation to technetium-99m methoxyisobutylisonitrile scintimammography findings
29. F-18-FDG and Tc-99m sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: A comparative study
30. Tc-99m MIBI scintigraphy in the assessment of neoadjuvant chemotherapy in breast carcinoma
31. The effect of chemotherapy on the uptake of Tc-99m sestamibi in breast cancer
32. Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: In vitro studies in multidrug-resistant breast tumor cells
33. Influence of cell concentration in limiting the therapeutic benefit of P-glycoprotein reversal agents
34. Carmichael J. Selective reversal of vinblastine resistance in multidrug-resistant cell lines by tamoxifen, toremifene and their metabolites
35. Circumvention of daunorubicin resistance by a new tamoxifen derivative, toremifene, in multidrug-resistant cell line
36. Toremifene enhances cell cycle block and growth inhibition by vinblastine in multidrug resistant human breast cancer cells
37. Toremifene and its metabolites enhance doxorubicin accumulation in estrogen receptor negative multidrug resistant human breast cancer cells
38. Toremifene: Pharmacologic and pharmacokinetic basis of reversing multidrug resistance
39. Targeting chemosensitizing doses of toremifene based on protein binding
40. Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine
41. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin
42. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi